### Solifenacin Encyclopedia Analysis

Paragraph 1: Overview and Structure

Solifenacin is a selective muscarinic receptor antagonist primarily used to treatOveractive bladder (OAB), its core function is to relieve frequent urination, urgency and urge incontinence. This article will start from four dimensions: pharmacological mechanism, clinical application, manufacturer and product name, and precautions for use, focusing on itsEfficacy and safety, the secondary content covers common preparations on the market and patient suitability.

Paragraph 2: Pharmacological mechanism and core functions

Solinaxin passedSpecifically blocks M3 receptors on bladder smooth muscle, inhibits the contractile effect of acetylcholine, thereby reducing the frequency of involuntary bladder contractions. Clinical data shows that it can reduce the number of daily urinations by up to 40% and reduce urge urinary incontinence episodes by 50% (Source:European Urology Journal). Compared with traditional drugs such as tolterodine, solifenacin has less impact on the M1/M4 receptors of the salivary glands.Reduce the incidence of dry mouth side effects by 30%(See the table below for data).

Paragraph 3: Clinical Application and Patient Adaptation

Solifenacin is suitable forAdult OAB patients over 18 years old, the standard dose is 5-10mg/day. The American Urological Association (AUA) guidelines state that it is particularly applicable to OAB patients with diabetes (source:AUA 2022 Guidelines). It should be noted that patients with severe hepatic and renal insufficiency need to adjust the dose. Common adverse reactions include constipation (16%) and blurred vision (5%).

Paragraph 4: Market products and production information

Major global manufacturers includeAstellas Pharmaceuticals (original drug Vesicare®), India's Sun Pharmaceuticals (generic drug Soliten®) and China's Qilu Pharmaceuticals (trade name: Ubida®). The bioequivalence difference between original drugs and generic drugs is <5%, but the price difference can be up to 60% (data source:FDA Orange Book).

Paragraph 5: Summary and Notes

As a first-line drug for OAB, solifenacin has both efficacy and tolerability advantages, but it needs to be avoided in combination with strong CYP3A4 inhibitors (such as ketoconazole). Patients should take medication under the guidance of a doctor and regularly assess residual urine volume. Its long-term safety has been verified by a 7-year follow-up study (Source:British Journal of Clinical Pharmacology).

Citation sources: European Urology Journal (2018), AUA Guidelines (2022), FDA Orange Book (2023)